ASIC Corporations (Capital Reductions and Reconstructions—Technical Disclosure Relief) Instrument 2017/242

This legislative instrument, made under subsection 1020F(1) of the Corporations Act 2001, modifies how Part 7.9 of the Act applies to two specific types of corporate transactions: eligible reconstructions and capital reduction offers. It grants technical disclosure relief by deleting a key content requirement for Product Disclosure Statements (PDS) and adding a clarification about deemed address provisions when documents accompany notices of meeting. Specifically, section 5 provides that Part 7.9 (financial product disclosure) applies in relation to a financial product being offered under an eligible reconstruction or which is the subject of a capital reduction offer as if Division 2 of that Part were modified in two ways. First, subsection 1013B(1) is omitted entirely. That subsection normally requires a PDS to contain all the information that a person would reasonably need to make an informed decision about the product. Its deletion means that for these transactions, the issuer does not need to include that standard content in a PDS, or arguably does not need to provide a PDS at all if the rest of Division 2 requires one. Second, a new subsection 1015C(6) is inserted after existing subsection 1015C(5). Section 1015C deals with when and how a PDS or statement must be given to a person. The new subsection (6) provides that, for the avoidance of doubt, where a statement is in or accompanies a notice of meeting of members of a company, foreign company or registered scheme, each member is taken to have nominated the address shown in the register of members (or equivalent for foreign companies) for the purpose of subparagraph 1015C(1)(a)(ii). That subparagraph requires the person giving the statement to send it to the person’s nominated address. This amendment removes any doubt about whether the register address qualifies as a nominated address for members when the statement is bundled with a meeting notice. The net effect is to relieve issuers of having to prepare and distribute a full PDS with all the usual content for these transactions, and to remove a potential technical defect about the delivery address.

The instrument centres on three interconnected definitions. A capital reduction offer is defined broadly: it means either a Part 2J.1 capital reduction offer or a foreign capital reduction offer. Both of those terms take their meaning from another ASIC instrument, the ASIC Corporations (Application Form Requirements) Instrument 2017/241, which is incorporated by reference. A Part 2J.1 capital reduction offer generally refers to an offer to buy back shares or reduce capital under Part 2J.1 of the Corporations Act - for example, selective buy‑backs, equal access buy‑backs, or other capital reductions approved by members. A foreign capital reduction offer extends the concept to offers made by foreign companies that are analogous to those reductions under their home law. An eligible reconstruction also has the same meaning as in ASIC 2017/241. That instrument defines eligible reconstructions as arrangements or compromises under Part 5.1 (schemes of arrangement) or certain reconstructions that involve the issue of financial products to members in exchange for their existing interests, often as part of a corporate restructure. The concept of offer is affected by sections 1010C and 1011C of the Act, which extend the meaning of offer to include invitations to apply for a financial product and offers made by or on behalf of an issuer. The relief modifies Division 2 of Part 7.9, which is the core disclosure division dealing with PDS content, providing, and updating obligations. By omitting subsection 1013B(1), the instrument removes the general requirement that a PDS contain information that a person would reasonably need to make an informed decision. However, note that other parts of Division 2 (such as the requirement that a PDS not be misleading or deceptive under s 1021B etc.) and other Divisions of Part 7.9 (e.g., advertising restrictions) are not modified. The instrument also explicitly notes that the relief is technical - it addresses what ASIC considered an unintended technical consequence of the Corporations Act requiring a PDS for these transactions even when members already receive detailed information through meeting notices and explanatory statements. The new subsection 1015C(6) is described as inserted “for the avoidance of doubt”, indicating ASIC viewed the register address as already sufficient but wanted to eliminate any litigation risk.

The instrument primarily affects companies, foreign companies, and registered schemes that undertake capital reductions or eligible reconstructions. This includes Australian public companies proposing selective buy‑backs, friendly takeovers structured as capital reductions, internal corporate restructures that involve the issue of new shares or other financial products to existing members, and foreign companies with an Australian register of members undertaking similar transactions. The directors and officers of those entities are the ones who need to ensure the relief is appropriately relied upon and that the terms of the instrument are satisfied. Members of those entities are affected because they will not receive a standalone PDS containing the full s 1013B(1) disclosure. Instead, they may receive only an explanatory statement or notice of meeting that contains less formal product disclosure. The new subsection 1015C(6) also affects members by deeming the register address as their nominated address for receipt of that statement, which means they cannot later argue that the document was not properly given if they have not updated their address on the register. ASIC itself is affected because it grants the relief and must oversee compliance with the modified Part 7.9. Practitioners - lawyers, company secretaries, compliance officers, and accountants - must advise clients on whether a particular transaction falls within the definitions and whether the relief applies. The instrument also cross‑references ASIC Corporations (Application Form Requirements) Instrument 2017/241, so anyone advising on a transaction must read both instruments together. The note at the end of section 5 points to another related instrument (ASIC 2025/613) for compromises or arrangements not covered by this section. Thus, the scope is narrower than all corporate reconstructions - only those that fit the “eligible reconstruction” definition are covered. Foreign companies with a place of business in Australia and an Australian register of members are explicitly included via the definition of foreign capital reduction offer and the new subsection 1015C(6)(b).

Under the modified Part 7.9, the issuer of the financial product no longer has the duty to include in a PDS all the information required by subsection 1013B(1) - that is, information a person would reasonably need to make an informed decision. However, the instrument does not abolish the duty to have a PDS at all. Division 2 of Part 7.9 contains other provisions that may still require a PDS to be prepared and given. For example, s 1012A requires a PDS to be given when an offer of a financial product is made. The instrument says Part 7.9 applies “as if Division 2 were modified by … omitting subsection 1013B(1)”. So the requirement to give a PDS remains, but the content of that PDS is no longer subject to the s 1013B(1) standard. In practice, the PDS could be a very short document or even the notice of meeting itself if it contains the minimal information required by other provisions. The new subsection 1015C(6) imposes a duty on the issuer to send the statement to the address in the register of members. It also gives the issuer a safe harbour: if the statement is in or accompanies a notice of meeting, the member is taken to have nominated the register address. That means the issuer does not need to obtain a separate nomination of address from each member for the purpose of that delivery. The rights of members are affected: they lose the right to receive a full‑disclosure PDS with all the content normally mandated. They retain the right to receive the notice of meeting and accompanying statement, but that statement may be less comprehensive. Members also have the right to have their address as shown on the register treated as their nominated address, so they cannot complain that the document was sent to the wrong address if it is sent to that register address. However, a member who has a different actual address and has not updated the register may not receive the document - that is a risk of the deemed nomination. The instrument does not alter any other rights, such as the right to vote on the resolution or the right to challenge the transaction under other provisions of the Act.

The instrument itself does not create or specify any penalties. Instead, it modifies the operation of Part 7.9, which contains its own penalty provisions. For example, s 1021B makes it an offence to give a PDS that is misleading or deceptive. That provision still applies to any PDS given under a capital reduction offer or reconstruction, even if the s 1013B(1) content is omitted. Similarly, ss 1012A and 1015C require the PDS or statement to be given in a timely manner; failure to do so could lead to civil or criminal penalties under the Act. The key enforcement consequence of this instrument is that reliance on it is a defence against any allegation that the PDS failed to include information required by s 1013B(1). ASIC has declared that the provision is omitted, so a prosecutor or plaintiff cannot point to that provision as a basis for liability if the issuer has followed the instrument’s terms. However, the issuer must still ensure it meets all other disclosure obligations. ASIC also has power under s 1020F(1) to revoke or vary the instrument, and may investigate whether the relief is being abused. If ASIC forms the view that a transaction does not actually meet the definition of capital reduction offer or eligible reconstruction, it could take enforcement action for non‑compliance with the unmodified Part 7.9. The note in the end of s 5 references another instrument for compromises or arrangements not covered here, implying that ASIC has considered the scope and may act if issuers try to stretch the definitions. Additionally, directors and officers may face personal liability under the general law (duty of care) if they rely on the relief without ensuring that members still receive adequate information to make informed decisions. The instrument is not a blank cheque; it is technical relief, not substantive exemption from disclosure obligations.

The instrument specifically modifies Division 2 of Part 7.9 of the Corporations Act only. It does not modify any other division of Part 7.9 (e.g., Division 1 - general duties, Division 3 - ongoing disclosure, Division 4 - advertising) or any other Part of the Act. Accordingly, other obligations remain in full force. For example, the general prohibition against misleading or deceptive conduct in s 1041H still applies to any statement made in connection with the offer. The instrument also cross‑references two other ASIC instruments: ASIC 2017/241 (Application Form Requirements) provides the definitions of “eligible reconstruction”, “Part 2J.1 capital reduction offer”, and “foreign capital reduction offer”. Anyone relying on this relief must therefore consult that instrument to ensure the transaction qualifies. The note at the end of s 5 points to ASIC Corporations (Compromises or Arrangements) Instrument 2025/613, which provides relief for offers made under certain reconstructions not covered by this section - presumably schemes of arrangement that do not fall within the “eligible reconstruction” definition. That instrument should be read alongside this one. The interaction with Chapter 2C of the Act (registers of members) is also relevant: the new s 1015C(6) explicitly refers to the register of members maintained under Chapter 2C for companies and registered schemes, and for foreign companies, the analogous register under foreign law. That means the reliability and accuracy of the register becomes critical for the deemed nomination. If the register is outdated, the member may not receive the document, but the issuer is still protected. There is also interaction with the general law of meeting notices and proxies. The relief only applies when a statement is “in or accompanies a notice of meeting of members”. That suggests the statement must be physically included with or attached to the notice. If the issuer separately posts a PDS and a meeting notice, the relief may not apply. The instrument does not override the Takeovers Panel’s guidance or the ASX Listing Rules, which may impose additional disclosure requirements for capital reductions or reconstructions.

The instrument was originally registered as F2017L00280 on 22 March 2017 and commenced on 23 March 2017. Section 2 (which would have been a provision about commencement) was repealed by operation of section 48D of the Legislation Act 2003, which automatically repeals self‑repealing commencement provisions. The only substantive amendment occurred via the ASIC Corporations (Amendment and Repeal) Instrument 2025/617 (F2025L01152), registered on 23 September 2025 and commencing on 24 September 2025. That amendment affected the note at the end of section 5. The original note likely referenced an earlier version of the compromises instrument; the amendment updated the note to refer to ASIC Corporations (Compromises or Arrangements) Instrument 2025/613. This change was necessary because the earlier compromises instrument had been replaced or re‑numbered. The amendment does not affect the substance of the relief itself. The compilation date is 24 September 2025, and the instrument is now Compilation No. 1. There are no uncommenced amendments. The amendment history in Endnote 4 is minimal: it records the repeal of s 2 and the amendment of s 5 (note). The instrument remains a relatively stable piece of technical relief.

The instrument does not itself record any court cases, and no litigation is referenced in the compilation. This is unsurprising for a legislative instrument that is rarely at the centre of disputes. Because it is a declaration made under s 1020F(1) of the Act, it is a form of legislative relief that can be judicially reviewed, but to date no reported decisions appear to have challenged the validity or interpretation of this particular instrument. The instrument’s terms are fairly clear, and the relief is narrow. Any litigation would likely arise in the context of a broader challenge to a capital reduction or reconstruction - for example, a member claiming they did not receive a proper PDS and the issuer relying on this instrument as a defence. A court would then need to interpret the definitions (e.g., whether a particular transaction is an “eligible reconstruction” as defined in the incorporated instrument) and whether the instrument validly modifies Part 7.9. The new subsection 1015C(6) was inserted “for the avoidance of doubt”, indicating ASIC’s awareness of potential arguments about address nomination. If such arguments had been litigated, the instrument would have been amended earlier. The absence of citations suggests the instrument has worked as intended without generating court challenges. However, practitioners should be aware that reliance on the instrument does not immunise the issuer from other claims, such as misleading conduct or breach of directors’ duties. In that sense, litigation risk remains, but it is not centred on the instrument itself.

Several traps exist for the unwary. First, the relief only modifies Division 2 of Part 7.9. It does not remove the obligation to give a PDS under s 1012A; it only removes the content requirement of s 1013B(1). That means a PDS must still exist, and it must not be misleading or deceptive. Some practitioners might assume no PDS is needed at all, which is incorrect. The instrument merely reduces the content burden, not the requirement to have and give a PDS. Second, the definitions of “capital reduction offer” and “eligible reconstruction” are not self‑contained; they are imported from ASIC 2017/241. That instrument may itself have been amended, and its definitions may be narrower than one expects. For example, a standard selective buy‑back may qualify, but an on‑market share buy‑back under a continuous disclosure waiver might not. You must check both instruments. Third, the relief applies only where the offer is “under” an eligible reconstruction or is “the subject of a capital reduction offer”. A transaction that is partly a reduction and partly a scheme of arrangement might fall into a gap. The note points to a different instrument for compromises or arrangements not covered, so one must ensure the correct instrument is used. Fourth, the new s 1015C(6) applies only “for the purpose of subparagraph (1)(a)(ii)” of s 1015C. That subparagraph deals with giving a statement to a person’s nominated address. If the statement is not given with a notice of meeting, or if the issuer sends it by some other means (e.g., email without a meeting notice), the deemed nomination does not apply, and the issuer must have a separate nomination. Fifth, the relief does not extend to Division 1 of Part 7.9 (e.g., s 1012A’s timing rules). If the meeting notice is sent more than 12 months after the offer is made, there may be a stale PDS issue. Sixth, the instrument only applies to “financial products” being offered. If the capital reduction involves a return of cash only (no financial product issued), there may be no offer of a financial product, and the relief is irrelevant. Seventh, the instrument is made under s 1020F(1) - a power to exempt or modify - but ASIC could revoke or vary it at any time, so practitioners should check the current version.

To rely on this instrument, an entity must first confirm that the transaction meets the definitions. This requires reading the ASIC Corporations (Application Form Requirements) Instrument 2017/241 to ensure the offer is a Part 2J.1 capital reduction offer or a foreign capital reduction offer, or that the reconstruction qualifies as an “eligible reconstruction”. Legal advice should be obtained on whether the specific transaction fits. If it does, the entity should prepare a PDS (or a document that serves as a PDS) but may omit the content otherwise required by s 1013B(1). Typically, the PDS might be the explanatory statement accompanying the notice of meeting, supplemented by a document that contains the information required by other provisions (e.g., the offer terms, fees, risks if material, and the issuer’s name). The entity must still ensure that the document is not misleading or deceptive, and that it contains all other information required by Division 2 of Part 7.9 (such as any updated information under s 1015B, and the expiry date). The statement should be included in or accompany the notice of meeting of members. For the delivery compliance, the entity should send the notice and statement to the member’s address as recorded in the register of members (or, for foreign companies, the equivalent register). It does not need to obtain a separate address nomination for that document. However, for subsequent documents (e.g., a supplementary PDS if the offer changes), the deemed nomination may not apply, so the issuer may need to rely on other provisions. The entity should also maintain records showing that the transaction fits the definitions and that the relief was relied upon. The notice of meeting should be properly convened under the company’s constitution and the Act. For foreign companies, the entity must ensure that the foreign law equivalent of a register of members is kept and that sending to that address is permissible. Finally, the entity should consider whether other ASIC instruments (e.g., 2025/613) might provide broader or more suitable relief. It is prudent to include a statement in the meeting materials that reliance is being placed on this instrument, as a matter of transparency and to avoid later disputes. Compliance with the modified Part 7.9 does not guarantee compliance with other laws, such as the Takeovers Code or the ASX Listing Rules, so those should be separately checked. Annual review of the instrument’s current status is advised, as ASIC may amend or replace it.